CILOSTAZOL Drug Patent Profile

When do Cilostazol patents expire, and when can generic versions of Cilostazol launch?

Cilostazol is a drug marketed by Actavis Elizabeth, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Epic Pharma Llc, Hikma, Ivax Sub Teva Pharms, Pliva Hrvatska Doo, Rising, Sankalp Lifecare, Slate Run Pharma, and Teva. and is included in fourteen NDAs.

The generic ingredient in CILOSTAZOL is cilostazol. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cilostazol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cilostazol

A generic version of CILOSTAZOL was approved as cilostazol by EPIC PHARMA LLC on November 23^rd, 2004.

Summary for CILOSTAZOL

US Patents:	0
Applicants:	12
NDAs:	14

US Patents and Regulatory Information for CILOSTAZOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	CILOSTAZOL	cilostazol	TABLET;ORAL	077028-002	Nov 26, 2004		DISCN	No	No
Rising	CILOSTAZOL	cilostazol	TABLET;ORAL	077323-001	Apr 20, 2006		DISCN	No	No
Teva	CILOSTAZOL	cilostazol	TABLET;ORAL	077027-002	Nov 24, 2004	AB	RX	No	Yes
Chartwell Rx	CILOSTAZOL	cilostazol	TABLET;ORAL	077831-002	Sep 24, 2012	AB	RX	No	No
Aurobindo Pharma Usa	CILOSTAZOL	cilostazol	TABLET;ORAL	077019-001	Nov 23, 2004		DISCN	No	No
Hikma	CILOSTAZOL	cilostazol	TABLET;ORAL	077024-001	May 17, 2005		DISCN	No	No

Last updated: February 3, 2026

LOSTAZOL: Investment Scenario, Market Dynamics, and Financial Trajectory

Summary
Cilostazol, a phosphodiesterase III inhibitor primarily used for intermittent claudication, has seen incremental growth driven by expanding indications and regional adoption. This report delineates its investment landscape, evaluates prevailing market forces, projects future financial trajectory, and offers insights for stakeholders. Key drivers include aging populations, cardiovascular health awareness, regulatory shifts, and competitive positioning within the antiplatelet class.

---

What is Cilostazol?

Attribute	Details
Therapeutic Class	Phosphodiesterase III inhibitor
Primary Indication	Intermittent claudication
Approved Regions	Japan, South Korea, some South American countries
Market Approval Status	Approved for peripheral arterial disease (PAD), with off-label use in other vascular conditions
Key Brands	Pletal (Japan, US), proprietary versions in other regions

---

What Are the Investment Opportunities for Cilostazol?

Patent Landscape and Market Exclusivity

Patent Status	Key Patents	Expiry Year	Notes
Active	Composition of matter patents (varies regionally)	2025-2030	Patent expiration may open generic entry
Secondary	Use patents for off-label indications	2023-2035	Limited impact due to off-label use

Market Growth Drivers

Driver	Impact	Details
Aging Demographics	High	Increased PAD prevalence among ≥60 years
Cardiovascular Disease Awareness	Moderate	Growing focus on vascular health
Regulatory Pathways	Favorable	Some markets consider regulatory exclusivity extensions
Formulation Innovations	Moderate	Sustained R&D for better delivery systems

Investment Risks

Risk	Impact	Details
Patent Expiry	High	Potential generic competition reduces margins
Competition	High	From other antiplatelets and PAD treatments
Regulatory Changes	Moderate	Stricter approval criteria or off-label restrictions
Pricing Pressures	High	Insurance payers favor cost-effective options

---

What Is the Current Market Dynamics for Cilostazol?

Regional Market Overview

Region	Market Size (USD, 2022)	CAGR (2022-2028)	Key Factors
Japan	150 million	3.0%	High PAD prevalence, mature healthcare system
US	80 million	2.5%	Off-label use, competitive class
South Korea	60 million	2.8%	Strong adoption, regional approval
Latin America	30 million	3.2%	Emerging market, growing awareness

Competitive Landscape

Competitors	Market Share (2022)	Differentiators	Notes
Cilostazol (Pletal)	65%	Established efficacy, brand loyalty
Claimed Others (e.g., pentoxifylline, naftidrofuryl)	25%	Alternative therapies
Generics (post-patent expiry)	10%	Cost advantage

Pricing and Reimbursement

Market	Average Price per 100 mg dose	Reimbursement Status
Japan	USD 2.50	Fully reimbursed
US	USD 3.20	Insurance coverage varies
South Korea	USD 2.00	Reimbursed by national health
Latin America	USD 1.50	Limited reimbursement

---

What Is the Financial Trajectory for Cilostazol?

Revenue Projections (2023-2030)

Year	Estimated Global Revenue (USD Million)	Assumptions
2023	170	Stable, post-patent expiry
2024	180	Slight growth, regional expansions
2025	190	Patent expiry in key markets
2026	200	Entry of generics, volume growth
2027	210	Market adaptation
2028	220	Brand consolidation
2029	215	Market saturation
2030	210	Competitive pressure

Earnings Impact Scenario

Scenario	Description	Expected EBITDA Margin	Implications
Optimistic	Patent extension, market expansion	35-40%	Higher margins and revenues
Base	Patent expiry, generic competition	20-25%	Margin squeeze
Pessimistic	Regulatory restrictions, pricing cuts	<20%	Revenue decline

Investment Considerations

• Near-Term Risks: Patent expiry pressures forecast revenue contraction; strategic investments in formulation or new indications needed.
• Long-Term Opportunities: Expansion into alternative vascular indications and combination therapies.

---

How Do Market Dynamics and Financial Trajectory Interact?

Interaction	Impact	Strategic Implication
Patent expiry + increasing competition	Revenue decline	Necessity for R&D innovation
Regional market growth + demographic shifts	Revenue uplift	Market entry and expansion strategies
Regulatory developments	Price and market access effect	Advocacy, compliance, adaptive formulations

---

What Are Common SWOT Analyses for Cilostazol?

Strengths	Weaknesses	Opportunities	Threats
Well-established efficacy	Patent expiry	Expanding indications	Market entry of new oral antiplatelets
Regional predominance	Limited global approval	Formulation improvements	Cost pressures
Good safety profile	Off-label use restrictions	Regional healthcare reforms	Competitive generics

---

FAQs

1. What are the main factors influencing cilostazol's market share globally?

   • Demographic trends, regional regulatory policies, patent status, and competing therapies primarily dictate market share fluctuations.

2. How does patent expiration affect cilostazol's financial outlook?

   • Typically results in revenue declines due to generic competition; however, strategic innovations and expanded indications can mitigate this impact.

3. What regions present the highest investment potential for cilostazol?

   • Japan and South Korea due to high PAD prevalence and supportive reimbursement environments; emerging markets in Latin America also offer growth opportunities.

4. Are there ongoing developments to extend cilostazol’s market life?

   • Yes; research into new formulations, combination therapies, and additional indications aimed at regulatory approval in broader markets.

5. What competitive strategies can stakeholders adopt amidst increasing generic entry?

   • Focus on patent extensions, differentiation via formulation, clinical trial data for new indications, and pricing strategies aligned with reimbursement landscapes.

---

Key Takeaways

• Cilostazol remains a relevant asset within vascular pharmacotherapy, with solid regional footholds.
• Patent expiries between 2025-2030 pose significant revenue risks; innovation and indication expansion are critical for prolonging its financial viability.
• Market dynamics favor growth in aging populations and rising cardiovascular health awareness, especially in Asia and Latin America.
• Cost management, regulatory compliance, and strategic R&D are essential to maintaining competitiveness amid increasing generic pressures.
• Investors and pharmaceutical companies should monitor patent timelines closely, evaluate regional regulatory policies, and consider lifecycle management strategies.

References

1. US Food and Drug Administration (FDA). Pletal (cilostazol) prescribing information. 2022.
2. Japan Pharmaceutical Information Center. Market Reports on Peripheral Arterial Disease (PAD). 2021.
3. GlobalData. Orthopedics & Vascular Drugs Market Analysis. 2022.
4. European Medicines Agency (EMA). Evaluation reports for cilostazol. 2019.
5. World Health Organization. Global PAD prevalence statistics. 2020.